Department of Hepatobiliary & Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Zhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, 310009, China.
Immunotherapy. 2023 Feb;15(3):135-147. doi: 10.2217/imt-2021-0075. Epub 2023 Feb 13.
The study aimed to evaluate the effect of a galectin-9 and PD-L1 combined blockade in pancreatic ductal adenocarcinoma (PDAC). The expression of galectin-9 and PD-L1 was analyzed in PDAC. Furthermore, we explored the therapeutic effect of combined anti-galectin-9 and anti-PD-L1 therapy on pancreatic cancer . Higher expression of galectin-9 and PD-L1 was observed in human PDAC compared with the normal pancreas. Furthermore, in a murine model of PDAC, combined anti-galectin-9 and anti-PD-L1 treatment was associated with a greater decrease in tumor growth compared with treatment with either antibody therapy alone. Anti-PD-L1 antibody treatment for PDAC patients may be enhanced by inhibiting galectin-9.
本研究旨在评估半乳糖凝集素-9 和 PD-L1 联合阻断在胰腺导管腺癌 (PDAC) 中的作用。分析了 PDAC 中半乳糖凝集素-9 和 PD-L1 的表达。此外，我们还探讨了联合抗半乳糖凝集素-9 和抗 PD-L1 治疗对胰腺癌的治疗效果。与正常胰腺相比，人 PDAC 中观察到半乳糖凝集素-9 和 PD-L1 的表达更高。此外，在 PDAC 的小鼠模型中，与单独使用任何一种抗体治疗相比，联合使用抗半乳糖凝集素-9 和抗 PD-L1 治疗可使肿瘤生长减少更多。抑制半乳糖凝集素-9 可能会增强抗 PD-L1 抗体治疗 PDAC 患者的效果。
